BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31291378)

  • 21. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
    Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
    Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.
    Bryant A; Palma CA; Jayaswal V; Yang YW; Lutherborrow M; Ma DD
    Mol Cancer; 2012 Feb; 11():8. PubMed ID: 22348345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
    Mattsson G; Turner SH; Cordell J; Ferguson DJ; Schuh A; Grimwade LF; Bench AJ; Weinberg OK; Marafioti T; George TI; Arber DA; Erber WN; Mason DY
    Haematologica; 2010 Apr; 95(4):670-3. PubMed ID: 20015883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights into the biology of acute myeloid leukemia with mutated NPM1.
    Brunetti L; Gundry MC; Goodell MA
    Int J Hematol; 2019 Aug; 110(2):150-160. PubMed ID: 30632059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of Nucleophosmin Mutant Gene Expression of Leukemia Cells Using Raman Spectroscopy.
    Li M; Wu Y; Chi M; Wang Y; Zhu M; Gao S
    Appl Spectrosc; 2023 Jul; 77(7):689-697. PubMed ID: 37306050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
    Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.
    Xie G; Ivica NA; Jia B; Li Y; Dong H; Liang Y; Brown D; Romee R; Chen J
    Nat Biomed Eng; 2021 May; 5(5):399-413. PubMed ID: 33046866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
    Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
    Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
    Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleophosmin gene mutations in acute myeloid leukemia.
    Chen W; Rassidakis GZ; Medeiros LJ
    Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
    Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
    J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
    Andresen V; Erikstein BS; Mukherjee H; Sulen A; Popa M; Sørnes S; Reikvam H; Chan KP; Hovland R; McCormack E; Bruserud Ø; Myers AG; Gjertsen BT
    Cell Death Dis; 2016 Dec; 7(12):e2497. PubMed ID: 27906185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
    Liso A; Castiglione F; Cappuccio A; Stracci F; Schlenk RF; Amadori S; Thiede C; Schnittger S; Valk PJ; Döhner K; Martelli MF; Schaich M; Krauter J; Ganser A; Martelli MP; Bolli N; Löwenberg B; Haferlach T; Ehninger G; Mandelli F; Döhner H; Michor F; Falini B
    Haematologica; 2008 Aug; 93(8):1219-26. PubMed ID: 18603563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
    Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
    Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.